Literature DB >> 18691939

Products of anti-CD3/anti-CD28 activated lymphocytes induce differentiation and maturation of dendritic cells and have adjuvant-like activity in vitro and in vivo.

Kristina M Harris1, Petra Lenz, Kim G Hankey, Thomas MacVittie, Ann Farese, Kaori Nakajima, Kenichiro Hasumi, Dean L Mann.   

Abstract

Dendritic cells (DC) orchestrate immune responses under direction of cytokines/chemokines in their microenvironment. To investigate the influence of that generated during T cell activation, we stimulated peripheral blood mononuclear cells (PBMC) with anti-CD3 and anti-CD28 coated beads and tested cell-free culture supernatants (lymphocyte conditioned medium, LCM) for cytokine/chemokine composition and biologic activity. LCM contained a battery of mediators important in the biology of myeloid (mDC) and plasmacytoid (pDC) DC. LCM differentiated monocytes into functional immature mDC, and induced maturation of immature mDC. LCM also augmented maturation and IFNalpha-production of CpG-treated pDC. Functional activity of LCM-derived DC was confirmed by their ability to enhance in vitro recall T cell responses and substantially augment in vivo cellular and humoral immune responses to various vaccines in non-human primates. These results demonstrate that products of anti-CD3/anti-CD28 stimulated PBMC generate biologically active DC in vitro and function as a vaccine adjuvant in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691939     DOI: 10.1016/j.clim.2008.06.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  3 in total

1.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.

Authors:  Samantha Solito; Erika Falisi; Claudia Marcela Diaz-Montero; Andrea Doni; Laura Pinton; Antonio Rosato; Samuela Francescato; Giuseppe Basso; Paola Zanovello; Georgiana Onicescu; Elizabeth Garrett-Mayer; Alberto J Montero; Vincenzo Bronte; Susanna Mandruzzato
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

2.  Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy.

Authors:  Kenichiro Hasumi; Yukimasa Aoki; Ryuko Watanabe; Kim G Hankey; Dean L Mann
Journal:  Cancers (Basel)       Date:  2011-04-28       Impact factor: 6.639

3.  Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy.

Authors:  Kenichiro Hasumi; Yukimasa Aoki; Ryuko Wantanabe; Dean L Mann
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.